Stocks and Investing Stocks and Investing
Thu, December 5, 2024
[ Thu, Dec 05th 2024 ] - Thomas Matters
The CRA is Watching TFSA Holders: Here Are Some Red Flags to Avoid
[ Thu, Dec 05th 2024 ] - Thomas Matters
The UK tech stocks worth owning
[ Thu, Dec 05th 2024 ] - Thomas Matters
Google's new gen AI video model Veo available on Vertex AI private preview
[ Thu, Dec 05th 2024 ] - Thomas Matters
3 ASX 300 shares with ex-dividend dates before the end of 2024
[ Thu, Dec 05th 2024 ] - Thomas Matters
2 high-yield ASX dividend shares for Australian retirees
[ Thu, Dec 05th 2024 ] - Thomas Matters
5 things to watch on the ASX 200 on Thursday
[ Thu, Dec 05th 2024 ] - Thomas Matters
Dow Jones Futures: Bitcoin Hits $100,000; Nvidia Ready To Run?
[ Thu, Dec 05th 2024 ] - Thomas Matters
Here's Why Dave Inc. (DAVE) is a Great Momentum Stock to Buy
[ Thu, Dec 05th 2024 ] - Thomas Matters
Tony Robbins: These 3 Investments Can Make You Rich
[ Thu, Dec 05th 2024 ] - Thomas Matters
CMC Invest launches a flexible Isa - here's how i .. mes the latest platform to offer tax-free account
[ Thu, Dec 05th 2024 ] - Thomas Matters
News Highlights: Top Company News of the Day - Thursday at 1 AM ET
[ Thu, Dec 05th 2024 ] - MSN
Here are the top 10 ASX 200 shares today
[ Thu, Dec 05th 2024 ] - The Motley Fool
Why Intuitive Machines Stock Just Crashed 14%
[ Thu, Dec 05th 2024 ] - The Motley Fool
Why C3.ai Stock Soared 51% in November
[ Thu, Dec 05th 2024 ] - The Daily Telegraph
In 1964, we recommended five shares - we'd buy these again today
[ Thu, Dec 05th 2024 ] - Seeking Alpha
The Cost Of Euphoria: Why Palantir's Rally Could Be A Mirage
[ Thu, Dec 05th 2024 ] - Motley Fool Australia
1 Australian energy stock to buy confidently and 1 to avoid for now
[ Thu, Dec 05th 2024 ] - Thomas Matters
Best mid cap mutual funds to invest in December 2024
[ Thu, Dec 05th 2024 ] - Thomas Matters
Top Australian financial stocks to buy now
Wed, December 4, 2024
[ Wed, Dec 04th 2024 ] - Thomas Matters
Billionaire Ken Griffin Just Increased Citadel's Position in This Unstoppable ETF by 277%
[ Wed, Dec 04th 2024 ] - Thomas Matters
Top AI Stocks For 2024: Investment Tips From An Expert
[ Wed, Dec 04th 2024 ] - Thomas Matters
Intel Axes CEO Pat Gelsinger: Is It Time to Buy the Struggling Chip Stock?
[ Wed, Dec 04th 2024 ] - Thomas Matters
Traders Focus On Central Bank Action in India After Poor GDP Growth
[ Wed, Dec 04th 2024 ] - Thomas Matters
Top oil and gas stocks to buy now in Australia
[ Wed, Dec 04th 2024 ] - Thomas Matters
Brokers Suggest Investing in MakeMyTrip (MMYT): Read This Before Placing a Bet
[ Wed, Dec 04th 2024 ] - Thomas Matters
SIMON BROWN: Yes, buy top stocks for the bottom drawer
[ Wed, Dec 04th 2024 ] - Thomas Matters
2 Dividend-Paying Stocks Suze Orman Says To Consider Investing In
[ Wed, Dec 04th 2024 ] - Thomas Matters
10 Of The Best Investment Apps For Android Users (According To User Rating)
[ Wed, Dec 04th 2024 ] - Thomas Matters
Understanding The Difference Between Value VS. Market Cap Weighted
[ Wed, Dec 04th 2024 ] - Thomas Matters
Why Janux Therapeutics Crushed the Market Today

Why Janux Therapeutics Crushed the Market Today


Published on 2024-12-04 22:02:56 - Thomas Matters, WOPRAI
  Print publication without navigation

  • News of an analyst's price-target hike plus a new round of capital-raising were the sparks that ignited Janux Therapeutics ( JANX 11.65%) stock on Wednesday. The clinical-stage biotech's share price ended the day nearly 12% higher, and this was on a very good day for the exchange with the S&P 500 rising by 0.6%.

Janux Therapeutics (NASDAQ: JANX) experienced a significant surge in its stock price on December 4, 2024, after the company announced positive interim data from its ongoing Phase 1 clinical trial for JANX007, a novel T-cell engager aimed at treating prostate cancer. The trial results indicated a favorable safety profile and promising early signs of efficacy, with several patients showing reductions in PSA levels and tumor size. This news led to a 45% increase in Janux Therapeutics' stock value, far outpacing the broader market's performance. The positive data has heightened investor confidence in the company's pipeline, particularly in its ability to develop effective cancer treatments, thereby driving the stock's impressive performance for the day.

Read the Full The Motley Fool Article at:
[ https://www.fool.com/investing/2024/12/04/why-janux-therapeutics-crushed-the-market-today/ ]
Contributing Sources